This finding establishes a rationale for the use of FMN/CAL as a glioma-adjuvant treatment by demonstrating that they can increase malignant glioma sensitivity to temozolomide through suppressing NOS2-dependent cell survival [80] (Table 3). This evidence concerns the gene NOS2 and glioma.